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Medication-Assisted Treatment for 
Opioid Use Disorder
Summary
The opioid overdose epidemic continues 
to claim lives across the country with a 
record 47,600 overdose deaths in 2017. 
(This number represents 67.8% of the 
70,237 overdose deaths from all drugs) 
[CDC 2018a]. More Americans now die 
every year from drug overdoses than in 
motor vehicle crashes [CDC 2016]. The 
crisis is taking an especially devastating 
toll on certain parts of the U.S. work-
force. High rates of opioid overdose 
deaths have occurred in industries with 
high injury rates and physically demand-
ing working conditions such as con-
struction, mining, or fishing [Massachu-
setts Department of Public Health 2018; 
CDC 2018b]. Certain job factors such as 
high job demands, job insecurity, and 
lack of control over tasks have also been 
linked to opioid use [Kowalski-McGraw 
et al. 2017]. Medication-assisted treat-
ment (MAT) (also known as medication-
based treatment*) has been shown to be 
effective for many people with opioid 
use disorder [SAMHSA 2015b; Nation-
al Academies of Sciences, Engineering, 
and Medicine 2019]. In addition to pro-
viding general information about MAT, 
this document provides information for 
employers wishing to assist or support 
workers with opioid use disorder.
Background
Challenges related to prescription drug 
misuse, illicit drug use, and addiction 
affect individual workers, their fami-
lies, and both large and small business-
es. In a 2017 National Safety Council 
survey, 70% of employers reported suf-
fering the negative effects of prescrip-
tion drug misuse; noting positive drug 
tests, absenteeism, injuries, accidents, 
and overdoses [Hersman 2017]. In 
2013, the total U.S. societal costs of pre-
scription opioid use disorder (OUD) 
and overdoses were $78 billion. Of that, 
about $2.8 billion was for treatment 
[Florence et al. 2016].†
In 2016, individuals with insurance 
coverage received $2.6 billion in ser-
vices for treatment of opioid addiction 
and overdose, a dramatic increase from 
$0.3 billion in 2004 (based on claims 
data from large employers). Of that 
$2.6 billion, $1.3 billion was for outpa-
tient treatment, $911 million was for 
inpatient care, and $435 million was 
for prescription drugs [Cox et al. 2018]. 
Employers may save up to $2,607 per 
worker annually (based on 2012‒2014 
data) by getting workers into treatment 
[NSC et al. 2016; NORC].
Despite these findings, 80% of individu-
als in need of treatment for a substance 
use disorder in 2016 did not receive 
treatment [CBHSQ 2017]. Making med-
ication-assisted treatment (MAT) more 
readily available to people with OUD 
can help diminish the opioid crisis in the 
United States.
*Note that some experts recommend the term “medication-based treatment” or MBT instead 
of MAT. This change in nomenclature aligns with the premise that OUD is a chronic disorder 
for which medications are first-line treatments (often an integral part of a person’s long-term 
treatment plan) rather than complementary or temporary aids on the path to recovery [Na-
tional Academies of Sciences, Engineering, and Medicine 2019].
†The White House Council of Economic Advisers [CEA 2017] estimated the economic cost of 
these deaths related to opioids “using conventional economic estimates for valuing life rou-
tinely used by U.S. Federal agencies.” The CEA report “also adjusts for underreporting of opi-
oids in overdose deaths, includes heroin-related fatalities, and incorporates nonfatal costs 
of opioid misuse.” CEA estimates that in 2015, the economic cost of the opioid crisis was 
$504.0 billion, or 2.8 percent of GDP that year.”
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Treatment
What is medication-
assisted treatment (MAT)?
MAT uses medications approved by the 
U.S. Food and Drug Administration 
(FDA) in combination with counseling 
and behavioral therapies to treat OUD 
involving misuse of either prescription 
or illicit opioids. The medications reduce the cravings for 
and the euphoria (extreme pleasure) experienced with opi-
oids [SAMHSA 2015b]. Some medications may also reduce 
the risk of subsequent overdose. Three drugs are commonly 
used in MAT:
  Methadone is a full opioid agonist, which means that it 
works similarly to other opioids such as heroin, morphine, 
or fentanyl. Unlike other opioids, methadone acts much 
more slowly in the body. This slower action helps to re-
duce the euphoric highs and lows associated with other 
types of opioids while diminishing withdrawal symptoms. 
Methadone treatment is available only through a feder-
ally regulated opioid treatment program (OTP) and re-
quires those in the program to report to the OTP daily or 
near daily to obtain the medication. Methadone itself can 
be addictive and misused, so it is important that it be used 
only as prescribed and under medical supervision.
  Buprenorphine is a partial opioid agonist, which means 
that it does not have the full effect of other semi-synthet-
ic opioids in the same class, such as heroin or oxycodo-
ne. The drug is long-acting, works slowly, and, similar to 
methadone, helps prevent the intense cravings and with-
drawal symptoms associated with opioid use. Buprenor-
phine is available by itself or in combination with nal-
oxone, an opioid antagonist that reverses or prevents the 
effects of opioids. Adding naloxone discourages the mis-
use of buprenorphine. While naloxone has no effect when 
the combination (buprenorphine/naloxone) is used as di-
rected by sublingual tablet or buccal film, the naloxone 
does work to block the effect of buprenorphine when the 
combination is injected or used nasally. MAT using bu-
prenorphine is available in healthcare settings outside of 
an OTP under certain circumstances. The Drug Addic-
tion Treat Act of 2000 allows physicians who meet cer-
tain qualifications to obtain a waiver to treat OUD with 
buprenorphine in primary care settings. Such waivers 
may make this treatment more accessible to those seeking 
treatment. Like methadone, it is possible for buprenor-
phine to be misused when not taken as prescribed.  
  Naltrexone is an opioid antagonist that blocks the eu-
phoric and sedative effects of opioids such as heroin or 
morphine. It also reduces cravings for opioids [SAMH-
SA 2015b; NIH 2018a]. This medication may also be pre-
scribed outside of an OTP.
Table 1 lists the formulations and possible side effects of each 
of these medications.
In addition to the side effects, serious drug interactions be-
tween MAT and other drugs (including alcohol) are also 
possible.
What are the typical steps in medication-
assisted treatment (MAT)?
Treatment for OUD begins with stabilization and opioid 
withdrawal management followed by medication mainte-
nance combined with counseling or behavioral therapy. Un-
derlying health conditions that may be influencing opioid 
Table 1. Formulations and side effects of medications used in medication-assisted treatment (MAT).
Drug Formulations‡ Potential adverse side effects
Methadone Tablet (Dolophine)
Oral concentrate (Methadose)
Respiratory depression, heart rhythm problems, low 
blood pressure, upset stomach, vomiting, constipa-
tion, dizziness, light-headedness, sedation, weakness
Buprenorphine
(Subutex)
Patch (Butrans)
Intradermal implant (Probuphine) 
Injection (Sublocade, Buprenex)
Sublingual tablet
Constipation, nausea, vomiting, headache, drowsi-
ness, sedation, insomnia, lack of energy, weakness
Buprenorphine/ 
Naloxone
(in combination)
Buccal film (Belbuca, Bunavail)
Sublingual tablet (Subutex, Zubsolv)
Sublingual film (Cassipa, Suboxone)
Constipation, nausea, vomiting, headache, insomnia, 
lack of energy
Naltrexone Oral (Revia, Depade)
Injectable suspension for extended  
release (Vivitrol)
Upset stomach, vomiting, diarrhea, stomach pain, 
headache, anxiety, dizziness, drowsiness, lack of en-
ergy, joint and muscle pain
Sources: NIH 2018a; IBM Micromedex DRUGDEX 2018; ASAM 2015; Leshner 2019
‡Some formulations have generic versions available.
use should also be addressed. In later phases of treatment, 
healthcare providers work with patients to determine when 
the medication(s) can be tapered or stopped.
What is the typical length of treatment?
Length of treatment is highly variable with all three MAT 
drugs and spans from months to years. Long-term treatment 
is often needed to prevent relapses. A decision to taper off 
medication depends on factors such as compliance, tolerance, 
adverse effects, and a patient’s progress toward abstinence 
from opioids. Tapering off often takes several months [ASAM 
2015]. Removing someone from MAT abruptly or premature-
ly may increase the risk of relapse and subsequent overdose.
What is an opioid treatment  
program (OTP)?
OTPs are housed in facilities that provide substance abuse 
treatment including MAT for OUD. MAT patients treated in 
OTPs must receive counseling, which can include different 
forms of behavioral therapy. These facilities are accredited 
by the Substance Abuse and Mental Health Services Admin-
istration (SAMHSA), licensed to operate by the state where 
located, and registered with the U.S. Drug Enforcement 
Administration (DEA) [SAMHSA 2015a]. Some MAT med-
ications are only available through an OTP, while others can 
be obtained in other healthcare settings.
Can drugs used as part of medication-
assisted treatment (MAT) cause side 
effects that impair work activities?
Research has shown that, when provided at the proper dose, 
medications used in MAT have no adverse effects on a per-
son’s intelligence, mental capability, physical functioning, 
or employability [SAMHSA 2015b]. However, side effects 
of the medication(s) may impair a person’s ability to drive, 
operate heavy machinery, or perform other functions safely. 
Side effects will vary depending on the specific medication, 
dosage, and duration of treatment. Workers with safety-sen-
sitive jobs may be subject to restrictions or limits on the jobs 
or duties they perform while using these medications. These 
restrictions may include operating motor vehicles, forklifts, 
cranes, and other types of heavy equipment, or making de-
cisions that can affect the safety and health of others (such 
as dispatchers, operations managers, or other jobs requir-
ing high levels of cognitive function or judgement). Case-
by-case determinations by qualified occupational healthcare 
providers may be necessary based on the potential for im-
pairment resulting from MAT. Reasonable accommodations 
by the employer should be considered when appropriate. 
When starting MAT, the worker should avoid driving and 
hazardous work activities until dosages are stabilized, side ef-
fects are managed, and impairment risks related to the work 
to be performed are assessed. Side effects often diminish over 
time [ASAM 2015; IBM Micromedex DRUGDEX 2018].
Gaining Access to Medication-
Assisted Treatment (MAT)
Does employer health insurance cover 
medication-assisted treatment (MAT)?
The Affordable Care Act requires most insurers to cover 
treatment for substance use disorder. In addition, the Mental 
Health Parity and Addiction Equity Act (MHPAEA) of 2008 
requires health insurers and group health plans to provide 
benefits for behavioral health services at the same level as 
primary care. However, insurers may not cover all types of 
treatment for substance use disorder or may cover only cer-
tain treatments [SAMHSA 2017].  In addition, employers 
can often play an important role in influencing the level of 
healthcare and pharmacy benefits included in employer-
sponsored plans for the treatment of substance use disorders.
How can workers find medication-assisted 
treatment (MAT) healthcare providers?
Workers should turn to their physician and healthcare in-
surance provider for assistance. Insurers can provide infor-
mation about coverage and often have access to a network 
of preferred MAT providers. Some employers provide Em-
ployee Assistance Programs (EAP) offering counseling, sup-
port, and referrals. EAP and other member assistance pro-
grams  (present in many labor organizations) give workers 
a safe, confidential space to talk about personal issues (in-
cluding substance use disorder) and can provide referrals to 
local treatment facilities [ASSP 2018]. These types of pro-
grams can help foster a positive, supportive organizational 
culture that reduces the fear of serious repercussions when 
workers seek care.
Many states offer treatment programs for those without in-
surance coverage. Once a provider is identified, the work-
er should contact the provider for an appointment. Some 
programs are also able to offer walk-in services. In times 
of crisis, many people access services through hospital 
emergency rooms.
Other resources and information about locating addiction 
treatment centers can be found at https://findtreatment.samh-
sa.gov/ or by calling the National Helpline at 1-800-662-4357.
Regulations, Rights, and Worker 
Protections
Are opioid treatment programs (OTP) 
regulated?
OTPs are required by law to be accredited to help monitor 
the quality of care provided and the appropriate dispensing 
of opioid treatment drugs [SAMHSA 2015a; The Joint Com-
mission 2018]. For further information about these federal 
regulations, please refer to The Substance Abuse and Mental 
Health Services Administration’s (SAMHSA) Federal Guide-
lines for Opioid Treatment Programs.
What rights and protections are available 
to workers who have opioid use disorder 
(OUD)?
Employers should protect the privacy and confidentiality of 
all workers’ health-related information.
For employers subject to the Americans with Disabili-
ty Act (ADA), federal law safeguards people against job 
discrimination if they are undergoing MAT. Both the ADA 
and the Rehabilitation Act of 1973 forbid most employers 
from firing, refusing to hire, or discriminating (in the terms 
and conditions of employment) against any qualified job ap-
plicant or worker on the basis of a disability [Legal Action 
Center 2009]. In addition, the ADA, the Rehabilitation Act, 
and the Family Medical Leave Act (FMLA) give workers the 
right to take medical leave, which can include alcohol or drug 
treatment.
These federal laws cover employers in different ways. The 
ADA applies to all state and local government agencies and 
to private employers with fifteen or more workers. The Reha-
bilitation Act applies to federal agencies and to state and local 
government agencies and private employers that receive fed-
eral grants, contracts, or other federal aid. When federal law 
covers employers, they are prohibited from denying a job to, 
or firing, a worker based on a worker’s participation in MAT. 
They also must offer reasonable accommodation as needed to 
allow those with a disability to perform their job duties, un-
less the accommodation would cause undue hardship to the 
employer [American Addiction Centers 2018].
In addition to giving workers with OUD the right to take 
leave to focus on treatment, the FMLA also offers employers 
resources for managing that leave, and places other obliga-
tions and restrictions on the rights of workers.
More information from SAMHSA can be found here: 
Know Your Rights: Rights for Individual Medication-
Assisted Treatment.
How Employers Can Help
Employers can take the following steps to contribute to pre-
vention and treatment of OUD [NIOSH 2018; CDC 2017; 
Massachusetts Department of Public Health 2018; National 
Safety Council 2018; Kowalski-McGraw et al. 2017]:
  Ensure that work is safe and working conditions do not 
lead to worker injury or illness, or contribute to painful 
chronic conditions.
  Identify clinics that provide evidence-based treatment for
injured workers, including the adherence to opioid pre-
scribing guidelines.
  Provide adequate leave and other benefits after workplace
injury including flexibility in scheduling and receiving
medical care, support during recovery, and return to work.
  Take steps to manage workplace stressors and job insecu-
rity to the extent possible.
  Take steps to decrease the stigma associated with sub-
stance misuse through awareness building and supervisor
training.
  Educate workers about how drugs impair work activi-
ties, including driving, and encourage them to notify
their employers if they are taking medications that may
affect their ability to work safely so that a safe solution
can be determined.
  Develop and communicate clear drug-related workplace
policies that include an offer of assistance to workers
with OUD.
  Offer comprehensive treatment options to workers with
OUD, including healthcare coverage that provides MAT.
  Work with health plan providers and pharmacy benefit
managers to attend to inclusion of such coverage in em-
ployer health plans.
Employers should also consider the following steps when 
arranging services for their workers, or when working with 
others to select an MAT program or provider:
  Ensure that the MAT program is licensed or certified by
your state.
  Verify that the MAT program offers FDA-approved med-
ications to treat OUD.
  Check if the provider can offer or refer for psychological,
social, and family support in the treatment program.
  Look for independent evidence that the program offers
effective and proven treatment whenever possible
[SAMHSA 2019].
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